Trial Profile
An Open-Label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Motesanib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Amgen
- 26 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 02 Aug 2006 Status change
- 16 Dec 2005 New trial record.